18F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma
Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic
malignant melanoma. Although concerns have been raised that the inflammatory response …
malignant melanoma. Although concerns have been raised that the inflammatory response …
Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor
of response to immune checkpoint inhibitors (ICIs) in patients with advanced melanoma …
of response to immune checkpoint inhibitors (ICIs) in patients with advanced melanoma …
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
H Anwar, C Sachpekidis, J Winkler… - European journal of …, 2018 - Springer
Purpose Evaluation of response to immunotherapy is a matter of debate. The aim of the
present study was to evaluate the response of metastatic melanoma to treatment with …
present study was to evaluate the response of metastatic melanoma to treatment with …
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
C Sachpekidis, L Larribere, L Pan, U Haberkorn… - European journal of …, 2015 - Springer
Purpose Ipilimumab is a newly approved immunotherapeutic agent that has been shown to
provide a survival benefit in patients with metastatic melanoma. 18 F-FDG PET/CT has …
provide a survival benefit in patients with metastatic melanoma. 18 F-FDG PET/CT has …
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and …
K Prigent, C Lasnon, E Ezine, M Janson… - European journal of …, 2021 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) have significantly improved
survival in advanced melanoma. There is a need for robust biomarkers to identify patients …
survival in advanced melanoma. There is a need for robust biomarkers to identify patients …
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
C Sachpekidis, H Anwar, J Winkler… - European Journal of …, 2018 - Springer
Purpose The aim of the present study was to assess the value of interim 18 F-FDG PET/CT
performed after the first two cycles of ipilimumab treatment in the prediction of the final …
performed after the first two cycles of ipilimumab treatment in the prediction of the final …
[HTML][HTML] Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
PP van de Donk, TT Wind, JS Hooiveld-Noeken… - European Journal of …, 2021 - Springer
Purpose Immune checkpoint inhibitors can induce a T cell–mediated anti-tumor immune
response in patients with melanoma. Visualizing T cell activity using positron emission …
response in patients with melanoma. Visualizing T cell activity using positron emission …
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Purpose We aimed to investigate the role of FDG-PET/CT in monitoring of response and
immune-related adverse events (irAEs) following first-line combination-immune checkpoint …
immune-related adverse events (irAEs) following first-line combination-immune checkpoint …
Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT
JW Wachsmann, R Ganti, F Peng - Academic radiology, 2017 - Elsevier
Rationale and Objectives The purposes of this study were to provide a case-based overview
of various immune-mediated side effects detected by 18F-Fluorodeoxyglucose (F-18 FDG) …
of various immune-mediated side effects detected by 18F-Fluorodeoxyglucose (F-18 FDG) …
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
A Dimitrakopoulou-Strauss - Cancer Immunology, Immunotherapy, 2019 - Springer
Immune checkpoint inhibitors (ICI) have revolutionized therapy of metastatic melanoma. The
first ICI was ipilimumab, a cytotoxic T lymphocyte-associated Ag 4 (CLTA-4) inhibitor with …
first ICI was ipilimumab, a cytotoxic T lymphocyte-associated Ag 4 (CLTA-4) inhibitor with …
Related searches
- monitoring of patients metastatic melanoma
- ipilimumab therapy metastatic melanoma
- checkpoint inhibitors metastatic melanoma
- pet ct ipilimumab immunotherapy
- combination ipilimumab fdg pet
- immune response fdg pet
- pet imaging metastatic melanoma
- prediction of response metastatic melanoma
- nivolumab treatment fdg pet
- meta analysis metastatic melanoma
- monitoring of patients checkpoint inhibitors
- suv changes melanoma patients
- clinical response melanoma patients
- ipilimumab treatment metastatic melanoma
- metastatic melanoma patients absolute number
- predictive value metastatic melanoma